|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Biliary complications in liver transplantation: Impact of anastomotic technique and ischemic time on short- and long-term outcome显示文摘AIM: To elucidate the impact of various donor recipient and transplant factors on the development of biliary complications after liver transplantation.METHODS: We retrospectively reviewed 200 patients of our newly established liver transplantation(LT) program, who received full size liver graft. Biliary reconstruction was performed by side-to-side(SS), end-to-end(EE) anastomosis or hepeaticojejunostomy(HJ). Biliary complications(BC), anastomotic stenosis, bile leak, papillary stenosis, biliary drain complication, ischemic type biliary lesion(ITBL) were evaluated by studying patient records, corresponding radiologic imaging and reports of interventional procedures [e.g., endoscopic retrograde cholangiopancreatography(ERCP)]. Laboratory results included alanine aminotransferase(ALT), gammaglutamyltransferase and direct/indirect bilirubin with focus on the first and fifth postoperative day, six weeks after LT. The routinely employed external bile drain was examined by a routine cholangiography on the fifth postoperative day and six weeks after transplantation as a standard procedure, but also whenever clinically indicated. If necessary, interventional(e.g., ERCP) or surgical therapy was performed. In case of biliary complication, patients were selected, assigned to different complication-groups and subsequently reviewed in detail. To evaluate the patients outcome, we focussed on appearance of postoperative/post-interventional cholangitis, need for rehospitalisation, retransplantation, ITBL or death caused by BC.RESULTS: A total of 200 patients [age: 56(19-72), alcoholic cirrhosis: n = 64(32%), hepatocellular carcinoma: n = 40(20%), acute liver failure: n = 23(11.5%), cryptogenic cirrhosis: n = 22(11%), hepatitis B virus /hepatitis C virus cirrhosis: n = 13(6.5%), primary sclerosing cholangitis: n = 13(6.5%), others: n = 25(12.5%) were included. The median follow-up was 27 mo until June 2015. The overall biliary complication rate was 37.5%(n = 75) with anastomotic strictures(AS): n = 38(19%), bile leak(BL): n = 12(6%), biliary drain complication: n = 12(6%); papillary stenosis(PS): n = 7(3.5%), ITBL: n = 6(3%). Clinically relevant were only 19%(n = 38). We established a comprehensive classification for AS with four grades according to clinical relevance. The reconstruction techniques [SS: n = 164, EE: n = 18, HJ: n = 18] showed no significant impact on the development of BCs in general(all n < 0.05), whereas in the HJ group significantly less AS were found(P = 0.031). The length of donor intensive care unit stay over 6 d had a significant influence on BC development(P = 0.007, HR = 2.85; 95%CI: 1.33-6.08) in the binary logistic regression model, whereas other reviewed variables had not [warm ischemic time > 45 min(P = 0.543), cold ischemic time > 10 h(P = 0.114), ALT init > 1500 U/L(P = 0.631), bilirubin init > 5 mg/d L(P = 0.595), donor age > 65(P = 0.244), donor sex(P = 0.068), rescue organ(P = 0.971)]. 13%(n = 10) of BCs had no therapeutic consequences, 36%(n = 27) resulted in repeated lab control, 40%(n = 30) received ERCP and 11%(n = 8) surgical therapy. Fifteen(7.5%) patients developed cholangitis [AS(n = 6), ITBL(n = 5), PS(n = 3), biliary lesion BL(n = 1)]. One patient developed ITBL twelve months after LT and subsequently needed retransplantation. Rehospitalisation rate was 10.5 %(n = 21) [AS(n = 11), ITBL(n = 5), PS(n = 3), BL(n = 1)] with intervention or reinterventional therapy as main reasons. Retransplantation was performed in 5(2.5%) patients [ITBL(n = 1), acute liver injury(ALI) by organ rejection(n = 3), ALI by occlusion of hepatic artery(n = 1)]. In total 21(10.5%) patients died within the follow-up period. Out of these, one patient with AS developed severe fatal chologenic sepsis after ERCP.CONCLUSION: In our data biliary reconstruction technique and ischemic times seem to have little impact on the development of BCs. | Stefan Kienlein Wenzel Schoening Anne Andert Daniela Kroy Ulf Peter Neumann Maximilian Schmeding | 2015 | World Journal of Transplantation2015，5，4： | 14 |
| 2 | Extended surgical resection for xanthogranulomatous cholecystitis mimicking advanced gallbladder carcinoma: A case report and review of literature显示文摘Xanthogranulomatous 胆汁(XGC ) 是胆囊的破坏煽动性的疾病,很少包含邻近的机关并且模仿国王先进胆囊癌。诊断在病理学的检查以后仅仅通常是可能的。46 42 岁的女人被指我们包含肝核,正确的肝脑叶,恰好结肠的弯曲,和十二指肠的怀疑的胆囊癌症的中心。刷细胞学获得了由内视镜后退胆管造影术(ERC ) 出现了高级发育异常。病人经历了团的在团体切除术,由正确叶切除术,正确的半结肠切除术,和部分十二指肠的切除术组成。出人意料地揭示的病理学的检查一 XGC.Only,为有邻近的机关的直接参与的 XGC 的扩大外科的切除术的六个案例到目前为止被报导了。在这些情况中,与癌给 XGC 的可能的共存,恶意不能被排除,甚至在细胞学和 intraoperative 冰冻切片调查以后。在结论,由于源于在另外的方面上包围机关的高度好攻击的煽动性的侵略的一个方面和可能的复杂并发症上的胆囊癌的差的预后,它似乎这些案例应该被当作恶性瘤直到不那样证明。临床医生们应该包括 XGC 在之中可能微分在肝核群众诊断。 | Antonino Spinelli Guido Schumacher Andreas Pascher Enrique Lopez-Hanninen Hussain Al-Abadi Christoph Benckert Igor M Sauer Johann Pratschke Ulf P Neumann Sven Jonas Jan M Langrehr Peter Neuhaus | 2006 | World Journal of Gastroenterology2006，12，14： | 13 |
| 3 | Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer显示文摘 | Armin Thelen Sven Jonas Christoph Benckert Antonino Spinelli Enrico Lopez-H?nninen Birgit Rudolph Ulf Neumann Peter Neuhaus | 2007 | International Journal of Colorectal Disease2007，，10： | 2 |
| 4 | Outcome after liver re‐transplantation in patients with recurrent chronic hepatitis C显示文摘 | Marcus Bahra Ulf Peter Neumann Dietmar Jacob Thomas Berg Ruth Neuhaus Jan Michael Langrehr Peter Neuhaus | 2007 | Transplant International2007，，9： | 1 |
| 5 | Biomechanical analyses of prosthetic mesh repair in a hiatal hernia model显示文摘 | Patrick Hamid Alizai Sofie Schmid Jens Otto Christian Daniel Klink Anjali Roeth Jochen Nolting Ulf Peter Neumann Uwe Klinge | 2014 | J. Biomed. Mater. Res2014，，7： | 1 |
| 6 | Simultaneous splenectomy increases risk for opportunistic pneumonia in patients after liver transplantation显示文摘 | Ulf P. Neumann Jan M. Langrehr Udo Kaisers Martina Lang Volker Schmitz Peter Neuhaus | 2002 | Transplant International2002，，5： | 1 |
| 7 | SIGNIFICANCE OF A T-LYMPHOCYTOTOXIC CROSSMATCH IN LIVER AND COMBINED LIVER-KIDNEY TRANSPLANTATION显示文摘 | Ulf P. Neumann Martina Lang Anja Moldenhauer Jan M. Langrehr Matthias Glanemann Andreas Kahl Ullrich Frei Wolf O. Bechstein Peter Neuhaus | 2001 | Transplantation2001，，8： | 1 |
| 8 | Treatment of Patients with Recurrent Hepatitis C after Liver Transplantation with Peginterferon Alfa-2B Plus Ribavirin显示文摘 | Ulf Neumann Gero Puhl Marcus Bahra Thomas Berg Jan Michael Langrehr Ruth Neuhaus Peter Neuhaus | 2006 | Transplantation2006，，1： | 1 |
| 9 | Antiviral Treatment of Patients with Recurrent Hepatitis C After Liver Transplantation with Pegylated Interferon显示文摘 | Sven C. Schmidt Marcus Bahra Sandra Bayraktar Thomas Berg Maximilian Schmeding Johann Pratschke Peter Neuhaus Ulf Neumann | 2010 | Digestive Diseases and Sciences2010，，7： | 1 |
| 10 | Incidence of and risk factors for ischemic‐type biliary lesions following orthotopic liver transplantation显示文摘 | Christoph Heidenhain Johann Pratschke Gero Puhl Ulf Neumann Andreas Pascher Winfried Veltzke‐Schlieker Peter Neuhaus | 2009 | Transplant International2009，，1： | 1 |
| 11 | Mycophenolate Mofetil Monotherapy in Liver Transplantation: 5-Year Follow-Up of a Prospective Randomized Trial显示文摘 | Maximilian Schmeding Anja Kiessling Ruth Neuhaus Christoph Heidenhain Marcus Bahra Peter Neuhaus Ulf P. Neumann | 2011 | Transplantation2011，，8： | 1 |
| 12 | Role of IL28B Polymorphism in the Development of Hepatitis C Virus-Induced Hepatocellular Carcinoma, Graft Fibrosis, and Posttransplant Antiviral Therapy显示文摘 | Dennis Eurich Sabine Boas-Knoop Marcus Bahra Ruth Neuhaus Rajan Somasundaram Peter Neuhaus Ulf Neumann Daniel Seehofer | 2012 | Transplantation2012，，6： | 1 |
| 13 | Fibrosis progression after liver transplantation in patients with recurrent hepatitis C显示文摘 | Ulf P. Neumann Thomas Berg Marcus Bahra Daniel Seehofer Jan M. Langrehr Ruth Neuhaus Cornelia Radke Peter Neuhaus | 2004 | Journal of Hepatology2004，，5： | 1 |
| 14 | Long-Term Outcome of Liver Resection and Transplantation for Caroli Disease and Syndrome显示文摘 | Frank Ulrich Johann Pratschke Andreas Pascher Ulf P. Neumann Enrique Lopez-H?nninen Sven Jonas Peter Neuhaus | 2008 | Annals of Surgery2008，，2： | 1 |
| 15 | Fibrosis Progression in Hepatitis C Positive Liver Recipients After Sustained Virologic Response to Antiviral Combination Therapy (Interferon–Ribavirin Therapy)显示文摘 | Marcus Bahra Ulf P. Neumann Dietmar Jacob Jan M. Langrehr Thomas Berg Ruth Neuhaus Peter Neuhaus | 2007 | Transplantation2007，，3： | 1 |
| 16 | Targeted therapies in cholangiocarcinoma:light at the end of the tunnel?显示文摘The genetic landscape of cholangiocarcinoma(CCA)remains largely unexplored.It is one of the deadliest cancers(1),with the gold standard treatment for all anatomical forms(intrahepatic-iCCA,perihilar-pCCA and distal-dCCA)being surgical resection(with adjuvant capecitabine also recommended in the newest guidelines)(2,3).The importance of genetic markers in terms of postoperative and oncological outcomes is being increasingly recognized,but few actionable mutations have been identified so far(2,4).This is particularly pertinent for patients with advanced/irresectable disease,who rely on systemic therapy.Survival outcomes are poor in these patients[5-year survival up to 10%-(5)]and they would profit the most from novel,targeted therapies. | Iakovos Amygdalos Ulf Peter Neumann Sven Arke Lang | 2023 | Hepatobiliary Surgery and Nutrition2023，12，4： | 0 |
| 17 | Liver transplantation in malignant disease显示文摘Liver transplantation for malignant disease has gained increasing attention as part of transplant oncology.Following the implementation of the Milan criteria,hepatocellular carcinoma(HCC)was the first generally accepted indication for transplantation in patients with cancer.Subsequently,more liberal criteria for HCC have been developed,and research on this topic is still ongoing.The evident success of liver transplantation for HCC has led to the attempt to extend its indication to other malignancies.Regarding perihilar cholangiocarcinoma,more and more evidence supports the use of liver transplantation,especially after neoadjuvant therapy.In addition,some data also show a benefit for selected patients with very early stage intrahepatic cholangiocarcinoma.Hepatic epithelioid hemangioendothelioma is a very rare but nonetheless established indication for liver transplantation in primary liver cancer.In contrast,patients with hepatic angiosarcoma are currently not considered to be optimal candidates.In secondary liver tumors,neuroendocrine cancer liver metastases are an accepted but comparability rare indication for liver transplantation.Recently,some evidence has been published supporting the use of liver transplantation even for colorectal liver metastases.This review summarizes the current evidence for liver transplantation for primary and secondary liver cancer. | Sven Arke Lang Jan Bednarsch Zoltan Czigany Katharina Joechle Andreas Kroh Iakovos Amygdalos Pavel Strnad Tony Bruns Daniel Heise Florian Ulmer Ulf Peter Neumann | 2021 | World Journal of Clinical Oncology2021，12，8： | 0 |
| 18 | Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer显示文摘The mammalian target of rapamycin(mTOR)acts in two structurally and functionally distinct protein complexes,mTOR complex 1(mTORC1)and mTOR complex 2(mTORC2).Upon deregulation,activated mTOR signaling is associated with multiple processes involved in tumor growth and metastasis.Compared with mTORC1,much less is known about mTORC2 in cancer,mainly because of the unavailability of a selective inhibitor.However,existing data suggest that mTORC2 with its two distinct subunits Rictor and mSin1 might play a more important role than assumed so far.It is one of the key effectors of the PI3K/AKT/mTOR pathway and stimulates cell growth,cell survival,metabolism,and cytoskeletal organization.It is not only implicated in tumor progression,metastasis,and the tumor microenvironment but also in resistance to therapy.Rictor,the central subunit of mTORC2,was found to be upregulated in different kinds of cancers and is associated with advanced tumor stages and a bad prognosis.Moreover,AKT,the main downstream regulator of mTORC2/Rictor,is one of the most highly activated proteins in cancer.Primary and secondary liver cancer are major problems for current cancer therapy due to the lack of specific medical treatment,emphasizing the need for further therapeutic options.This review,therefore,summarizes the role of mTORC2/Rictor in cancer,with special focus on primary liver cancer but also on liver metastases. | Katharina Joechle Jessica Guenzle Claus Hellerbrand Pavel Strnad Thorsten Cramer Ulf Peter Neumann Sven Arke Lang | 2021 | World Journal of Gastrointestinal Oncology2021，13，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员